Novartis faces short-term challenges with patent expirations but shows long-term growth potential, making the stock a buy ...

The U.S. Court of Appeals for the Federal Circuit (CAFC) today issued a precedential decision reversing a district court’s ...

Light Horse’s CEO said the biotech’s initial focus will be on “high-value and historically challenging” oncology targets.

The Federal Circuit reversed a Delaware district court’s 2023 ruling axing a Novartis Pharmaceuticals Corp. patent covering ...

Marea’s Phase IIa study enrolled patients with hypertriglyceridemia—too much fat in the blood. The latest results showed the ...

Windward Bio has landed with a flurry of announcements, circling in a $200 million series A and offering up to $970 million ...

View the full release here: "I'm excited to welcome Alastair to Chemify to help us with building and scaling our ability to ...

Initial clinical data from Phase 1 SAD/MAD study of VAV1-directed molecular glue degrader (MGD) MRT-6160 expected in Q1 2025Additional clinical ...

Dr. Buchanan will helm Belharra’s research organization as the company progresses its lead immunology and oncology programs, advances activities ...

Johnson & Johnson received Priority Review of nipocalimab in generalized myasthenia gravis. GSK’s B7-H3-targeted ...

The U.S. 2nd Court of Appeals recently revisited a whistleblower lawsuit against Novartis, a Swiss pharmaceutical company, creating a new development in the enforcement of the Anti-Kickback Statute, ...

Light Horse Therapeutics is off to the races, rounding up a $62 million series A and tacking on a Novartis partnership that ...